How to Order

Choose how to get Thyrogen (thyrotropin alfa for injection) for your patients

Purchase directly from Sanofi Genzyme »

Wholesaler/ Distributor »

Specialty Pharmacy »


Not sure which one to choose?
call: 1-88-THYROGEN (1-888-497-6436)


Purchase directly from Sanofi Genzyme

Benefits of buying direct

  • Purchase in Real-time. Order what your patient needs, when they need it, with no storage
    • No minimum kit purchase
    • No third-party fees
    • Free delivery FedEx® Priority Overnight, Monday to Friday
    Download direct buy application

How ThyrogenONE can help

  • Billing and Coding Support
  • Same-Day Benefit Verification
  • Patient financial assistance
  • Dedicated Case Manager



Examples of


  • McKesson
  • Cardinal
  • Henry Schein


  • Priority
  • Theracom
  • CuraScript

Already have an existing relationship with a wholesaler or distributor?

  • You create and manage your wholesaler/distributor account

Your orders

  • You agree to terms with your preferred wholesaler/distributor, including pricing (may include a mark-up or additional fees)
  • Place your order directly with your preferred wholesaler/Distributor today

How ThyrogenONE can help

Specialty pharmacy

How ThyrogenONE can help coordinate specialty pharmacy fulfillment

  • Completes Benefit Verification and eligibility for Financial Assistance programs
  • Submits your prescription to the designated specialty pharmacy
  • Monitors status (with updates to you) until shipment

    Download Prescription Support Form

Specialty pharmacy

  • Contacts patient directly to review process and collect co-pay as appropriate
  • Bills ThyrogenONE Copay program electronically if patient is eligible
  • Ships to the treatment location
  • Bills health plan


*Complete online via ThyrogenONE online portal or Submit via email/fax


Do you need answers about billing and coding?

Does your patient have questions about financial assistance for THYROGEN?

ThyrogenONE provides you with access to paperless eOrdering through an online portal

Thyrogen® (thyrotropin alfa for injection) 0.9 mg/mL after reconstitution



There have been reports of death in non-thyroidectomized patients and in patients with distant metastatic thyroid cancer in which events leading to death occurred within 24 hours after administration of Thyrogen.

Caution should be exercised in patients who have substantial thyroid tissue still in situ or functional thyroid cancer metastases, specifically in the elderly and those with a known history of heart disease.

Hospitalization for administration of Thyrogen and post-administration observation in patients at risk should be considered.

There are post marketing reports of stroke in young women with risk factors for stroke, and neurological findings suggestive of stroke (e.g., unilateral weakness) occurring within 72 hours of Thyrogen administration in patients without known central nervous system metastases.

Patients should be well-hydrated prior to treatment with Thyrogen.

Sudden, rapid and painful enlargement of residual thyroid tissue or distant metastases can occur following treatment with Thyrogen.

Pretreatment with glucocorticoids should be considered for patients in whom tumor expansion may compromise vital anatomic structures.


The most common adverse reactions reported in clinical trials were nausea and headache.


Pregnancy Category C: Animal reproduction studies have not been conducted with Thyrogen. It is also not known whether Thyrogen can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Thyrogen should be given to a pregnant woman only if clearly needed.

Nursing Mothers: It is not known whether the drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Thyrogen is administered to a nursing woman.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

Geriatric Use: Results from controlled trials do not indicate a difference in the safety and efficacy of Thyrogen between adult patients less than 65 years and those over 65 years of age.

Renal Impairment: Elimination of Thyrogen is significantly slower in dialysis-dependent end stage renal disease patients, resulting in prolonged elevation of TSH levels.


Thyrogen is a thyroid stimulating hormone indicated for:

Diagnostic: Use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy.

Limitations of Use:

  • Thyrogen -stimulated Tg levels are generally lower than, and do not correlate with Tg levels after thyroid hormone withdrawal.
  • Even when Thyrogen -Tg testing is performed in combination with radioiodine imaging, there remains a risk of missing a diagnosis of thyroid cancer or underestimating the extent of the disease.
  • Anti-Tg Antibodies may confound the Tg assay and render Tg levels uninterpretable.

Ablation: Use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer.

Limitations of Use:

  • The effect of Thyrogen on long term thyroid cancer outcomes has not been determined.

See full Prescribing Information for more details.